Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) FCF Margin (2020 - 2025)

Vivos Therapeutics' FCF Margin history spans 6 years, with the latest figure at 138.44% for Q4 2025.

  • Quarterly results put FCF Margin at 138.44% for Q4 2025, down 5556.0% from a year ago — trailing twelve months through Dec 2025 was 100.92% (down 1265.0% YoY), and the annual figure for FY2025 was 100.92%, down 1265.0%.
  • FCF Margin for Q4 2025 was 138.44% at Vivos Therapeutics, down from 60.7% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 50.48% in Q4 2021 to a low of 170.69% in Q1 2022.
  • The 5-year median for FCF Margin is 96.01% (2021), against an average of 101.7%.
  • The sharpest move saw FCF Margin tumbled -10688bps in 2021, then soared 7764bps in 2023.
  • Year by year, FCF Margin stood at 50.48% in 2021, then crashed by -60bps to 81.01% in 2022, then dropped by -3bps to 83.13% in 2023, then increased by 0bps to 82.88% in 2024, then crashed by -67bps to 138.44% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 138.44%, 60.7%, and 111.91% for Q4 2025, Q3 2025, and Q2 2025 respectively.